Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma

Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01786616

Enrollment

Registered

2013-02-08

Start date

2005-01-31

Completion date

Unknown

Last updated

2013-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.

Interventions

DRUGFormoterol

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Mild to moderate asthma * Stable clinical conditions

Exclusion criteria

* Smokers * Current therapy with oral steroids * Exacerbations within the past 3 months

Design outcomes

Primary

Measure	Time frame
Peak Expiratory Flow (PEF) variability	PEF has been monitorized during the 4-week treatment period

Secondary

Measure	Time frame
Forced Expiratory Volume in 1 sec (FEV1) slope of the dose-response curve to salbutamol	At the end of the 4-week treatment period

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026